

Hans-Jürgen Mller

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11233107/hans-jurgen-moller-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

546
papers

37,357
citations

99
h-index

169
g-index

569
ext. papers

41,822
ext. citations

4.7
avg, IF

6.97
L-index

#	Paper	IF	Citations
546	Large recurrent microdeletions associated with schizophrenia. <i>Nature</i> , 2008 , 455, 232-6	50.4	1427
545	Common variants conferring risk of schizophrenia. <i>Nature</i> , 2009 , 460, 744-7	50.4	1350
544	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011 , 10, 52-77	14.4	1288
543	Identification of loci associated with schizophrenia by genome-wide association and follow-up. <i>Nature Genetics</i> , 2008 , 40, 1053-5	36.3	877
542	Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. <i>Journal of Affective Disorders</i> , 2000 , 59 Suppl 1, S5-S30	6.6	623
541	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 248-312	3.8	496
540	Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. <i>NeuroImage</i> , 2004 , 22, 83-94	7.9	492
539	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011 , 10, 138-51	14.4	489
538	Hippocampal changes in patients with a first episode of major depression. <i>American Journal of Psychiatry</i> , 2002 , 159, 1112-8	11.9	421
537	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017 , 174, 216-229	11.9	408
536	Disruption of the neurexin 1 gene is associated with schizophrenia. <i>Human Molecular Genetics</i> , 2009 , 18, 988-96	5.6	376
535	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 318-78	3.8	364
534	Social functioning in depression: a review. <i>Journal of Clinical Psychiatry</i> , 2000 , 61, 268-75	4.6	363
533	A genome-wide investigation of SNPs and CNVs in schizophrenia. <i>PLoS Genetics</i> , 2009 , 5, e1000373	6	357
532	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 334-85	3.8	346
531	Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. <i>Archives of General Psychiatry</i> , 2004 , 61, 95-102		336
530	Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. <i>Archives of General Psychiatry</i> , 2009 , 66, 700-12		321

529	Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. <i>Archives of General Psychiatry</i> , 2007 , 64, 410-6		316
528	Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. <i>American Journal of Psychiatry</i> , 2002 , 159, 1029-34	11.9	304
527	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 154-219	3.8	284
526	Depression-related variation in brain morphology over 3 years: effects of stress?. <i>Archives of General Psychiatry</i> , 2008 , 65, 1156-65		277
525	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 2-44	3.8	264
524	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 81-109	3.8	256
523	Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012 , 16, 77-84	2.4	255
522	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 5-43	3.8	252
521	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 85-116	3.8	251
520	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. <i>World Journal of Biological Psychiatry</i> , 2007 , 8, 67-104	3.8	249
519	Enlargement of the amygdala in patients with a first episode of major depression. <i>Biological Psychiatry</i> , 2002 , 51, 708-14	7.9	247
518	Accelerated brain aging in schizophrenia and beyond: a neuroanatomical marker of psychiatric disorders. <i>Schizophrenia Bulletin</i> , 2014 , 40, 1140-53	1.3	235
517	Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. <i>Psychiatry Research</i> , 1999 , 88, 163-71	9.9	235
516	Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. <i>Archives of Neurology</i> , 2002 , 59, 1267-72		225
515	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2005 , 6, 132-91	3.8	216
514	Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. <i>Biological Psychiatry</i> , 2003 , 53, 338-44	7.9	209
513	Lithium Trial in Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 922-931	4.6	208
512	A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. <i>Biological Psychiatry</i> , 2006 , 59, 721-9	7.9	199

511	Identifying depression in primary care: a comparison of different methods in a prospective cohort study. <i>BMJ, The</i> , 2003 , 326, 200-1	5.9	195
510	Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. <i>Journal of Psychiatry and Neuroscience</i> , 2008 , 33, 423-30 ^{4,5}	4.5	195
509	Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. <i>Schizophrenia Research</i> , 2010 , 121, 118-24	3.6	193
508	Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. <i>Brain</i> , 2005 , 128, 2626-44	11.2	182
507	Response and remission criteria in major depression--a validation of current practice. <i>Journal of Psychiatric Research</i> , 2010 , 44, 1063-8	5.2	174
506	Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. <i>Schizophrenia Research</i> , 2001 , 48, 125-36	3.6	174
505	Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. <i>Biological Psychiatry</i> , 2004 , 56, 581-6	7.9	173
504	Reduced hippocampal volume correlates with executive dysfunctioning in major depression. <i>Journal of Psychiatry and Neuroscience</i> , 2006 , 31, 316-23	4.5	171
503	Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 492-9	4.6	162
502	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. <i>NeuroImage</i> , 2007 , 38, 13-24	7.9	160
501	Childhood stress, serotonin transporter gene and brain structures in major depression. <i>Neuropsychopharmacology</i> , 2010 , 35, 1383-90	8.7	157
500	White matter microstructure underlying default mode network connectivity in the human brain. <i>NeuroImage</i> , 2010 , 49, 2021-32	7.9	155
499	Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2000 , 287, 187-90	3.3	151
498	A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. <i>Biological Psychiatry</i> , 2003 , 54, 34-9	7.9	150
497	Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. <i>Archives of General Psychiatry</i> , 2004 , 61, 177-83		149
496	Early detection and secondary prevention of psychosis: facts and visions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 117-28	5.1	146
495	Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. <i>Psychiatry Research</i> , 1999 , 88, 107-17	9.9	146
494	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. <i>NeuroImage</i> , 2007 , 34, 985-95 ⁹	9.9	144

493	Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. <i>Biological Psychiatry</i> , 2010 , 67, 161-7	7.9	142
492	Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study. <i>Journal of Psychiatric Research</i> , 2007 , 41, 168-73	5.2	142
491	Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. <i>NeuroImage</i> , 2008 , 39, 1600-12	7.9	140
490	Sound level dependence of the primary auditory cortex: Simultaneous measurement with 61-channel EEG and fMRI. <i>NeuroImage</i> , 2005 , 28, 49-58	7.9	139
489	Progression of corpus callosum atrophy in Alzheimer disease. <i>Archives of Neurology</i> , 2002 , 59, 243-8		139
488	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 115-24	3.8	139
487	Personality and attempted suicide. Analysis of anger, aggression and impulsivity. <i>Journal of Psychiatric Research</i> , 2009 , 43, 1262-71	5.2	137
486	Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. <i>Archives of Neurology</i> , 2005 , 62, 770-3		137
485	Reliability and plasticity of response inhibition and interference control. <i>Brain and Cognition</i> , 2013 , 81, 82-94	2.7	133
484	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 171-99	3.8	133
483	Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 826-37	4.6	133
482	Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. <i>Annals of Neurology</i> , 2002 , 52, 253-6	9.4	130
481	Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [¹²³ I] IBZM SPECT study. <i>Journal of Psychiatric Research</i> , 2006 , 40, 307-14	5.2	129
480	Prediction of treatment response in major depression: integration of concepts. <i>Journal of Affective Disorders</i> , 2007 , 98, 215-25	6.6	128
479	Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. <i>American Journal of Psychiatry</i> , 2001 , 158, 802-4	11.9	128
478	Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 859-69	5.8	126
477	Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. <i>Journal of Affective Disorders</i> , 2009 , 115, 439-49	6.6	125
476	The serotonin syndrome scale: first results on validity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998 , 248, 96-103	5.1	125

475	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. <i>World Journal of Biological Psychiatry</i> , 2003 , 4, 5-13	3.8	124
474	Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis. <i>Biological Psychiatry</i> , 2003 , 54, 465-73	7.9	121
473	Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. <i>Archives of General Psychiatry</i> , 2010 , 67, 692-700		120
472	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 5-40	3.8	118
471	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 76-95	3.8	116
470	Single-trial coupling of EEG and fMRI reveals the involvement of early anterior cingulate cortex activation in effortful decision making. <i>NeuroImage</i> , 2008 , 42, 158-68	7.9	116
469	Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. <i>Depression and Anxiety</i> , 2007 , 24, 185-95	8.4	115
468	Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. <i>Brain</i> , 2004 , 127, 811-24	11.2	115
467	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. <i>Journal of Psychiatric Research</i> , 2011 , 45, 309-21	5.2	112
466	Factor structure and external validity of the PANSS revisited. <i>Schizophrenia Research</i> , 2006 , 82, 213-23	3.6	112
465	The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. <i>Schizophrenia Research</i> , 2003 , 62, 37-44	3.6	112
464	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015 , 172, 617-29	11.9	111
463	Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1234-46	1.3	111
462	Associations between trait impulsivity and prepotent response inhibition. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012 , 34, 1016-32	2.1	108
461	COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 14-22	5.1	107
460	Opramamol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 59-65	1.7	106
459	A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1995 , 245, 45-9	5.1	106
458	Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early--and additional memory dysfunction in the late--prodromal state. <i>Schizophrenia Bulletin</i> , 2011 , 37, 861-73	1.3	105

457	Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1200-15	1.3	105
456	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. <i>World Journal of Biological Psychiatry</i> , 2007 , 8, 212-44	3.8	104
455	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. <i>World Journal of Biological Psychiatry</i> , 2004 , 5, 120-35	3.8	104
454	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 323-9	2.2	103
453	Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. <i>General Hospital Psychiatry</i> , 2004 , 26, 190-8	5.6	103
452	Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. <i>Biological Psychiatry</i> , 2003 , 54, 1406-13	7.9	101
451	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 69-86	3.8	101
450	Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 277-87	2.2	100
449	Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. <i>British Journal of Psychiatry</i> , 2007 , 51, s88-95	5.4	100
448	Syndromes and phenomenological subtypes underlying acute mania: a factor analytic study of 576 manic patients. <i>American Journal of Psychiatry</i> , 2002 , 159, 968-74	11.9	100
447	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. <i>Brain</i> , 2015 , 138, 2059-73	11.2	99
446	Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 405-12	5.8	99
445	Substance P serum levels are increased in major depression: preliminary results. <i>Biological Psychiatry</i> , 2003 , 53, 538-42	7.9	98
444	Treatment of depression with atypical features: a meta-analytic approach. <i>Psychiatry Research</i> , 2006 , 141, 89-101	9.9	97
443	Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. <i>American Journal of Psychiatry</i> , 2001 , 158, 1316-9	11.9	97
442	Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. <i>Schizophrenia Research</i> , 2007 , 97, 254-63	3.6	96
441	Management of the negative symptoms of schizophrenia: new treatment options. <i>CNS Drugs</i> , 2003 , 17, 793-823	6.7	95
440	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262 Suppl 1, 1-48	5.1	93

439	Reduced early auditory evoked gamma-band response in patients with schizophrenia. <i>Biological Psychiatry</i> , 2010 , 67, 224-31	7.9	93
438	Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. <i>Psychophysiology</i> , 2002 , 39, 175-181	4.1	93
437	Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. <i>International Clinical Psychopharmacology</i> , 2005 , 20, 121-30	2.2	92
436	Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics 1997 , 174, 255-259		91
435	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , 2015 , 25, 2318-25	1.2	89
434	Amygdala volume and depressive symptoms in patients with borderline personality disorder. <i>Biological Psychiatry</i> , 2006 , 60, 302-10	7.9	89
433	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 2-58	3.8	89
432	Duloxetine in the treatment of major psychiatric and neuropathic disorders. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 527-36	4.3	88
431	The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study. <i>Human Brain Mapping</i> , 2011 , 32, 1349-62	5.9	87
430	Anger- and aggression-related traits are associated with polymorphisms in the 5-HT-2A gene. <i>Journal of Affective Disorders</i> , 2006 , 96, 75-81	6.6	87
429	Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. <i>Journal of Neurology</i> , 2006 , 253, 794-800	5.5	86
428	Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2009 , 113, 210-7	3.6	85
427	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 142-70	3.8	84
426	Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. <i>American Journal of Psychiatry</i> , 2011 , 168, 408-17	11.9	84
425	Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. <i>American Journal of Psychiatry</i> , 2003 , 160, 1870-8	11.9	83
424	Cognitive functioning in euthymic bipolar I and bipolar II patients. <i>Bipolar Disorders</i> , 2008 , 10, 877-87	3.8	82
423	Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. <i>Journal of Affective Disorders</i> , 2001 , 63, 79-83	6.6	81
422	Orbitofrontal volume reductions during emotion recognition in patients with major depression. <i>Journal of Psychiatry and Neuroscience</i> , 2010 , 35, 311-20	4.5	80

421	Digitized analysis of handwriting and drawing movements in healthy subjects: methods, results and perspectives. <i>Journal of Neuroscience Methods</i> , 1999 , 90, 157-69	3	80
420	Electroconvulsive therapy and its different indications. <i>Dialogues in Clinical Neuroscience</i> , 2008 , 10, 105-117	5.7	80
419	Acute prefrontal rTMS increases striatal dopamine to a similar degree as D-amphetamine. <i>Psychiatry Research - Neuroimaging</i> , 2007 , 156, 251-5	2.9	79
418	The need for efficient long-term neuroleptic treatment in schizophrenic patients and the place of long acting injectable antipsychotics 2010 , 9,		78
417	Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. <i>Psychiatry Research</i> , 2003 , 119, 63-79	9.9	78
416	Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 102-14	3.8	77
415	Silexan in anxiety disorders: Clinical data and pharmacological background. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 412-420	3.8	76
414	Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 111-8	2.2	76
413	Altered brain activation during a verbal working memory task in subjects with amnesic mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 103-18	4.3	76
412	Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. <i>Schizophrenia Research</i> , 2003 , 64, 115-24	3.6	76
411	Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 166-176	2.4	75
410	Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication. <i>Clinical EEG and Neuroscience</i> , 2007 , 38, 78-81	2.3	75
409	Mixed depressive features predict manifold switch during treatment of depression in bipolar I disorder. <i>Journal of Affective Disorders</i> , 2004 , 78, 149-52	6.6	75
408	Der Verlauf schizophrener Psychosen 1986 ,		75
407	Hippocampal volume reduction and history of aggressive behaviour in patients with borderline personality disorder. <i>Psychiatry Research - Neuroimaging</i> , 2007 , 154, 157-70	2.9	74
406	Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin's dichotomy and beyond. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 2, 48-73 ¹	5.1	74
405	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 160-87	3.8	73
404	Opi Pramol for the treatment of somatoform disorders results from a placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2000 , 10, 211-7	1.2	73

403	Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. <i>Brain Research</i> , 1999 , 823, 104-12	3.7	73
402	Regional networks underlying interhemispheric connectivity: an EEG and DTI study in healthy ageing and amnesic mild cognitive impairment. <i>Human Brain Mapping</i> , 2009 , 30, 2098-119	5.9	72
401	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank. <i>International Journal of Neuropsychopharmacology</i> , 2015 , 18, pyv042	5.8	71
400	Brain-derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013 , 162B, 183-90	3.5	71
399	Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. <i>British Journal of Psychiatry</i> , 2009 , 195, 218-26	5.4	71
398	Auditory cortex and anterior cingulate cortex sources of the early evoked gamma-band response: relationship to task difficulty and mental effort. <i>Neuropsychologia</i> , 2007 , 45, 2294-306	3.2	71
397	The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. <i>Journal of Neuroscience</i> , 2011 , 31, 6684-91	6.6	70
396	Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. <i>American Journal of Psychiatry</i> , 2003 , 160, 376-9	11.9	70
395	Should the PANSS be rescaled?. <i>Schizophrenia Bulletin</i> , 2010 , 36, 455-60	1.3	69
394	White matter microstructure in relation to education in aging and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 17, 571-83	4.3	69
393	Neuronal correlates of emotional processing in patients with major depression. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 202-8	3.8	68
392	Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 241-4	3.8	68
391	Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer's disease: a diffusion tensor imaging and voxel-based morphometry study. <i>Cerebral Cortex</i> , 2007 , 17, 2276-82	5.1	67
390	Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003 , 27, 1101-11	5.5	67
389	Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1763-74	4.6	67
388	Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 6-26	3.8	66
387	HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 291-9	3.5	66
386	Clinical evaluation of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2007 , 22, 380-6	6	66

385	Dipole localization and test-retest reliability of frequency and duration mismatch negativity generator processes. <i>Brain Topography</i> , 1997 , 10, 3-8	4.3	64
384	Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 3, 3-23	5.1	64
383	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 2-32	3.8	63
382	Predictors of relapse in the year after hospital discharge among patients with schizophrenia. <i>Psychiatric Services</i> , 2012 , 63, 87-90	3.3	63
381	The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. <i>Schizophrenia Research</i> , 2002 , 56, 87-94	3.6	63
380	Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. <i>Schizophrenia Research</i> , 2010 , 116, 9-15	3.6	62
379	Decreased T cellular immune response in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2007 , 41, 3-7	5.2	62
378	Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251 Suppl 2, II13-20	5.1	62
377	Outcomes of 1014 naturalistically treated inpatients with major depressive episode. <i>European Neuropsychopharmacology</i> , 2010 , 20, 346-55	1.2	61
376	Reduced hippocampal volumes associated with the long variant of the tri- and diallelic serotonin transporter polymorphism in major depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 1003-7	3.5	61
375	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1005-14	1.2	60
374	Clinical predictors of response and remission in inpatients with depressive syndromes. <i>Journal of Affective Disorders</i> , 2011 , 133, 137-49	6.6	60
373	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. <i>Neurobiology of Aging</i> , 2006 , 27, 10-5	5.6	60
372	Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 205-18	4.6	60
371	Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 190-201	5.1	59
370	Antidepressants and driving ability: results from a clinical study. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1776-81	4.6	59
369	Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. <i>Biological Psychiatry</i> , 2005 , 57, 813-6	7.9	58
368	Molecular genetic findings in suicidal behavior: what is beyond the serotonergic system?. <i>Archives of Suicide Research</i> , 2007 , 11, 17-40	2.3	57

367	Temperament and character of suicide attempters. <i>Journal of Psychiatric Research</i> , 2008 , 42, 938-45	5.2	56
366	Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 217-28	5.8	56
365	Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 1997 , 228, 143-6	3.3	55
364	Cerebrospinal fluid tau protein shows a better discrimination in young old (. <i>Neuroscience Letters</i> , 1999 , 277, 21-4	3.3	55
363	P300 subcomponents reflect different aspects of psychopathology in schizophrenia. <i>Biological Psychiatry</i> , 1999 , 45, 116-26	7.9	55
362	German research network on schizophrenia-bridging the gap between research and care. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 321-9	5.1	54
361	Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. <i>European Neuropsychopharmacology</i> , 1993 , 3, 13-21	1.2	54
360	No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis. <i>Annals of General Psychiatry</i> , 2013 , 12, 26	3.4	53
359	Screening for depression in primary care: will one or two items suffice?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 215-23	5.1	53
358	Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 47-53	5.1	52
357	Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments. <i>Schizophrenia Research</i> , 2004 , 67, 175-83	3.6	52
356	Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. <i>Neuropsychopharmacology</i> , 2002 , 27, 638-45	8.7	52
355	Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2011 , 45, 234-41	5.2	51
354	Evaluation of the German WPA "program against stigma and discrimination because of schizophrenia--Open the Doors": results from representative telephone surveys before and after three years of antistigma interventions. <i>Schizophrenia Research</i> , 2008 , 98, 184-93	3.6	51
353	Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. <i>Psychopharmacology</i> , 2006 , 187, 86-94	4.7	51
352	A serine to glycine substitution at position 9 in the extracellular N-terminal part of the dopamine D3 receptor protein: no role in the genetic predisposition to bipolar affective disorder. <i>Psychiatry Research</i> , 1993 , 46, 253-9	9.9	51
351	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 6-23	3.8	50
350	Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 985-97	5.8	50

349	A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 212-20	2.2	50
348	Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 269-78	5.1	50
347	Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. <i>Neuroscience Letters</i> , 1999 , 259, 145-8	3.3	50
346	The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016 , 266, 725-736	5.1	50
345	Repeated S-ketamine infusions in therapy resistant depression: a case series. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 996-8	2.9	49
344	Alterations of the early auditory evoked gamma-band response in first-degree relatives of patients with schizophrenia: hints to a new intermediate phenotype. <i>Journal of Psychiatric Research</i> , 2011 , 45, 699-705	5.2	49
343	Is the PANSS used correctly? a systematic review. <i>BMC Psychiatry</i> , 2011 , 11, 113	4.2	49
342	Influence of trait anxiety on inhibitory control in alcohol-dependent patients: simultaneous acquisition of ERPs and BOLD responses. <i>Journal of Psychiatric Research</i> , 2008 , 42, 734-45	5.2	49
341	A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. <i>Neuropsychopharmacology</i> , 2006 , 31, 1335-44	8.7	49
340	Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. <i>Neuropsychopharmacology</i> , 2004 , 29, 1910-7	8.7	49
339	Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life". <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2000 , 250, 120-32	5.1	49
338	Association between brain structure and psychometric schizotypy in healthy individuals. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 544-9	3.8	48
337	Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. <i>Microbial Biotechnology</i> , 2007 , 1, 71-8	3.3	48
336	Placebo-controlled studies in depression: necessary, ethical and feasible. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 22-8	5.1	48
335	Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 83-93	5.1	48
334	Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. <i>Brain Research</i> , 1998 , 780, 356-9	3.7	47
333	A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. <i>European Neuropsychopharmacology</i> , 2008 , 18, 122-7	1.2	47
332	The impact of antipsychotics on psychomotor performance with regards to car driving skills. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 155-60	1.7	47

331	Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. <i>Neuropsychopharmacology</i> , 2001 , 25, 699-703	8.7	47
330	Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. <i>Drugs</i> , 1996 , 52, 625-38	12.1	47
329	The effects of methylphenidate on whole brain intrinsic functional connectivity. <i>Human Brain Mapping</i> , 2014 , 35, 5379-88	5.9	46
328	Methylphenidate effects on neural activity during response inhibition in healthy humans. <i>Cerebral Cortex</i> , 2013 , 23, 1179-89	5.1	46
327	The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 367-84	5.1	46
326	Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials. <i>Wiener Medizinische Wochenschrift</i> , 2010 , 160, 547-56	2.9	46
325	Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 1-16	5.1	46
324	Evidence for beneficial effects of antidepressants on suicidality in depressive patients: a systematic review. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 329-43	5.1	46
323	Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. <i>Psychopharmacology</i> , 2003 , 166, 271-5	4.7	46
322	Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. <i>Archives of Neurology</i> , 1999 , 56, 467-73		46
321	Newer and Older Monoamine Oxidase Inhibitors. <i>CNS Drugs</i> , 1995 , 3, 145-158	6.7	46
320	Functional neural correlates of psychometric schizotypy: an fMRI study of antisaccades. <i>Psychophysiology</i> , 2012 , 49, 345-56	4.1	45
319	Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 476-96	5.1	45
318	Digitized analysis of abnormal hand-motor performance in schizophrenic patients. <i>Schizophrenia Research</i> , 2000 , 45, 133-43	3.6	45
317	Quetiapine in the treatment of schizophrenia and related disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 219-35	3.1	45
316	Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis. <i>Schizophrenia Research</i> , 2010 , 123, 175-87	3.6	44
315	NOS-I and -III gene variants are differentially associated with facets of suicidal behavior and aggression-related traits. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 42-8	3.5	44
314	Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 127-37	5.1	43

313	Anterior cingulate cortex does not differ between patients with major depression and healthy controls, but relatively large anterior cingulate cortex predicts a good clinical course. <i>Psychiatry Research - Neuroimaging</i> , 2008 , 163, 76-83	2.9	43
312	Neuropsychological impairments predict the clinical course in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 5, 28-34	5.1	43
311	Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. <i>World Journal of Biological Psychiatry</i> , 2005 , 6, 247-63	3.8	43
310	Risperidone: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 803-18	4	43
309	Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression?. <i>Journal of Affective Disorders</i> , 2001 , 67, 141-6	6.6	43
308	Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. <i>Schizophrenia Research</i> , 2000 , 44, 145-50	3.6	43
307	A large replication study and meta-analysis in European samples provides further support for association of AH11 markers with schizophrenia. <i>Human Molecular Genetics</i> , 2010 , 19, 1379-86	5.6	42
306	Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. <i>Archives of General Psychiatry</i> , 2009 , 66, 1045-54		42
305	Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 129-40	5.1	42
304	Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. <i>Acta Psychiatrica Scandinavica</i> , 2000 , 102, 54-7	6.5	42
303	Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis. <i>Schizophrenia Research</i> , 2010 , 123, 160-74	3.6	41
302	Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. <i>Drugs</i> , 2007 , 67, 1541-66	12.1	41
301	Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 360-70	5.1	41
300	Recent progress in pharmacological and non-pharmacological treatment options of major depression. <i>Current Pharmaceutical Design</i> , 2006 , 12, 503-15	3.3	41
299	Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. <i>Brain</i> , 2007 , 130, 1745-58	11.2	41
298	Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 432-7	5.1	41
297	Effectiveness and safety of benzodiazepines. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 2S-11S	1.7	41
296	Prediction of outcome in the psychosis prodrome using neuroanatomical pattern classification. <i>Schizophrenia Research</i> , 2016 , 173, 159-165	3.6	40

295	Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. <i>Psychopathology</i> , 2012 , 45, 276-85	3.4	40
294	Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2002 , 194, 15-9	3.2	40
293	Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?. <i>European Neuropsychopharmacology</i> , 2011 , 21, 370-8	1.2	39
292	An early improvement threshold to predict response and remission in first-episode schizophrenia. <i>British Journal of Psychiatry</i> , 2010 , 196, 460-6	5.4	39
291	Antidepressant-associated manifold states in acute treatment of patients with bipolar-I depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998 , 248, 296-300	5.1	39
290	Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. <i>Journal of Psychiatric Research</i> , 2005 , 39, 101-8	5.2	39
289	Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. <i>World Journal of Biological Psychiatry</i> , 2000 , 1, 75-91	3.8	39
288	Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. <i>Neuropsychobiology</i> , 1994 , 30, 160-72	4	39
287	[I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. <i>Journal of Psychiatry and Neuroscience</i> , 2007 , 32, 234-40	4.5	39
286	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 86-119	3.8	38
285	Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: an fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2008 , 163, 248-59	2.9	38
284	P300 subcomponents in obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2002 , 36, 399-406	2	38
283	Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 198-222	3.8	37
282	State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. <i>World Journal of Biological Psychiatry</i> , 2000 , 1, 204-14	3.8	37
281	Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. <i>Journal of Psychiatric Research</i> , 2009 , 43, 519-25	5.2	36
280	Inefficient neural activity in patients with schizophrenia and nonpsychotic relatives of schizophrenic patients: evidence from a working memory task. <i>Journal of Psychiatric Research</i> , 2009 , 43, 1185-94	5.2	36
279	Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 402-12	5.1	36
278	Atypical neuroleptics: a new approach in the treatment of negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999 , 249 Suppl 4, 99-107	5.1	36

277	The impact of homocysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 899-906	4.6	36
276	The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1880-6	4.6	36
275	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 82-90	2.4	35
274	Pharmacological treatment of negative symptoms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 567-78	5.1	35
273	The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 181-9	5.8	35
272	Risk factors for suicides of inpatients with depressive psychoses. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998 , 248, 141-7	5.1	35
271	Treatment Response in First-episode Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012 , 10, 78-87	3.4	34
270	Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. <i>Psychopharmacology</i> , 2011 , 216, 17-27	4.7	34
269	Novel schizophrenia risk gene TCF4 influences verbal learning and memory functioning in schizophrenia patients. <i>Neuropsychobiology</i> , 2011 , 63, 131-6	4	34
268	Lack of association between serotonin 5-HT1B receptor gene polymorphism and suicidal behavior 2003 , 116B, 69-71		34
267	Repetitive transcranial magnetic stimulation : does it have potential in the treatment of depression?. <i>CNS Drugs</i> , 2003 , 17, 383-403	6.7	34
266	Effectiveness studies: advantages and disadvantages. <i>Dialogues in Clinical Neuroscience</i> , 2011 , 13, 199-207	5.7	34
265	The diagnosis and treatment of generalized anxiety disorder. <i>Deutsches A&#x0308;rztblatt International</i> , 2013 , 110, 300-9; quiz 310	2.5	33
264	SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2008 , 42, 963-70	5.2	33
263	The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002 , 252, 226-31	5.1	33
262	Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. <i>Depression and Anxiety</i> , 2003 , 18, 140-3	8.4	33
261	Therapeutic efficacy of the Ginkgo special extract EGb761 within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 173-189	3.8	33
260	How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 721-730	5.8	32

259	The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 82-90	3.8	32
258	Negative symptoms in depressed and schizophrenic patients: how do they differ?. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 954-8	4.6	32
257	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014 , 264, 567-75	5.1	31
256	Internal capsule size associated with outcome in first-episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259, 278-83	5.1	31
255	Development of DSM-V and ICD-11: tendencies and potential of new classifications in psychiatry at the current state of knowledge. <i>Psychiatry and Clinical Neurosciences</i> , 2009 , 63, 595-612	6.2	31
254	Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 25-39	5.1	31
253	5-HT2A SNPs and the Temperament and Character Inventory. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007 , 31, 1275-81	5.5	31
252	Non-neuroleptic approaches to treating negative symptoms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 108-16	5.1	31
251	In-vivo analysis of the human planum temporale (PT): does the definition of PT borders influence the results with regard to cerebral asymmetry and correlation with handedness?. <i>Psychiatry Research - Neuroimaging</i> , 2001 , 107, 99-115	2.9	31
250	Selecting methodologies for the evaluation of differences in time to response between antidepressants. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 694-9	4.6	31
249	One-year functional outcomes of naturalistically treated patients with schizophrenia. <i>Psychiatry Research</i> , 2012 , 198, 378-85	9.9	30
248	Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 147-56	1.7	30
247	Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trial of treatment with atypical antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 335-44	5.1	30
246	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261 Suppl 3, 207-45	5.1	29
245	P300 subcomponents and clinical symptoms in schizophrenia. <i>International Journal of Psychophysiology</i> , 2002 , 43, 237-46	2.9	28
244	Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1293-307	4.6	28
243	The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. <i>Journal of Psychopharmacology</i> , 2016 , 30, 40-7	4.6	27
242	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: Results of the first-episode study within the German research network on schizophrenia. <i>Schizophrenia Research</i> , 2016 , 170, 168-76	3.6	27

241	Subjective emotional over-arousal to neutral social scenes in paranoid schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 59-68	5.1	27
240	The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 162-70	3.8	27
239	Tiagabine improves panic and agoraphobia in panic disorder patients. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 656-7	4.6	27
238	Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019 , 269, 183-193	5.1	27
237	Bipolar disorder and schizophrenia: distinct illnesses or a continuum?. <i>Journal of Clinical Psychiatry</i> , 2003 , 64 Suppl 6, 23-7; discussion 28	4.6	27
236	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. <i>European Neuropsychopharmacology</i> , 2013 , 23, 887-94	1.2	26
235	Impulsivity is related to striatal dopamine transporter availability in healthy males. <i>Psychiatry Research - Neuroimaging</i> , 2013 , 211, 251-6	2.9	26
234	Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 683-97	4.1	26
233	The free choice whether or not to respond after stimulus presentation. <i>Human Brain Mapping</i> , 2009 , 30, 2971-85	5.9	26
232	Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 843-51	1.9	26
231	Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. <i>Journal of Affective Disorders</i> , 2008 , 108, 271-8	6.6	26
230	Do effectiveness ("real world") studies on antipsychotics tell us the real truth?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 257-70	5.1	26
229	Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 729-38	3.8	25
228	Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 3-16	5.1	25
227	Switch to mania after slow rTMS of the right prefrontal cortex. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 249	4.6	25
226	Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 483-501	3.8	24
225	Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>Schizophrenia Research</i> , 2014 , 152, 478-86	3.6	24
224	Disentangling the adult attention-deficit hyperactivity disorder endophenotype: parametric measurement of attention. <i>Journal of Abnormal Psychology</i> , 2011 , 120, 890-901	7	24

223	ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia. <i>NeuroImmunoModulation</i> , 2005 , 12, 54-9	2.5	24
222	Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study. <i>Neuropsychobiology</i> , 2003 , 47, 212-8	4	24
221	Prefrontal cortex modulation of mood and emotionally induced facial expressions: a transcranial magnetic stimulation study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 206-12	2.7	24
220	Design of clinical trials of antidepressants: should a placebo control arm be included?. <i>CNS Drugs</i> , 2001 , 15, 755-64	6.7	24
219	Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999 , 249 Suppl 4, 27-36	5.1	24
218	The Speed of Visual Attention and Motor-Response Decisions in Adult Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2015 , 78, 107-15	7.9	23
217	Response trajectories in "real-world" naturalistically treated schizophrenia patients. <i>Schizophrenia Research</i> , 2012 , 139, 218-24	3.6	23
216	Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 726-31	1.7	23
215	GABAA receptors as targets for novel anxiolytic drugs. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 231-7	3.8	23
214	On the descriptive validity of ICD-10 schizophrenia: empirical analyses in the spectrum of non-affective functional psychoses. <i>Psychopathology</i> , 2003 , 36, 152-9	3.4	23
213	Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 44-8	5.1	23
212	Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2018 , 27,	4.3	22
211	EEG correlates of visual short-term memory as neuro-cognitive endophenotypes of ADHD. <i>Neuropsychologia</i> , 2016 , 85, 91-9	3.2	22
210	Multivariate patterns of brain-cognition associations relating to vulnerability and clinical outcome in the at-risk mental states for psychosis. <i>Human Brain Mapping</i> , 2012 , 33, 2104-24	5.9	22
209	Attitude towards adherence in patients with schizophrenia at discharge. <i>Journal of Psychiatric Research</i> , 2009 , 43, 1294-301	5.2	22
208	Akathisia and suicidal ideation in first-episode schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 694-8	1.7	22
207	ABCG1 gene variants in suicidal behavior and aggression-related traits. <i>European Neuropsychopharmacology</i> , 2007 , 17, 410-6	1.2	22
206	Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 99-107	5.1	22

205	Corpus callosum and P300 in schizophrenia. <i>Schizophrenia Research</i> , 2001 , 49, 107-19	3.6	22
204	State of the art: treatment of bipolar disorders. <i>CNS Neuroscience and Therapeutics</i> , 2012 , 18, 214-8	6.8	21
203	Functional outcomes in schizophrenia: employment status as a metric of treatment outcome. <i>Current Psychiatry Reports</i> , 2012 , 14, 229-36	9.1	21
202	Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 36-44	3.8	21
201	Agomelatine: The evidence for its place in the treatment of depression. <i>Core Evidence</i> , 2010 , 4, 171-9	4.9	21
200	Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 30-8	3.8	21
199	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. <i>Journal of Psychiatric Research</i> , 2010 , 44, 487-92	5.2	21
198	Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. <i>Psychiatry Research</i> , 2008 , 158, 297-305	9.9	21
197	In-vivo topography of structural alterations of the anterior cingulate in patients with schizophrenia: new findings and comparison with the literature. <i>Schizophrenia Research</i> , 2007 , 96, 34-45	3.6	21
196	Evidence of agomelatine's antidepressant efficacy: the key points. <i>International Clinical Psychopharmacology</i> , 2007 , 22 Suppl 2, S15-9	2.2	21
195	Classification of functional psychoses and its implication for prognosis: comparison between ICD-10 and DSM-IV. <i>Psychopathology</i> , 2004 , 37, 110-7	3.4	21
194	Novel antipsychotics in the long-term treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2004 , 5, 9-19	3.8	21
193	Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. <i>Journal of Affective Disorders</i> , 2004 , 83, 237-42	6.6	21
192	Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. <i>Journal of Psychiatric Research</i> , 2002 , 36, 131-5	5.2	21
191	Investigation of a possible diencephalic pathology in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2002 , 115, 127-35	2.9	21
190	Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 217-24	5.1	21
189	In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999 , 26, 862-8	8.8	21
188	Dopamine D3 receptor Gly9/Ser9 polymorphism and schizophrenia: no increased frequency of homozygosity in German familial cases. <i>Schizophrenia Research</i> , 1996 , 20, 181-6	3.6	21

187	A neuropsychological investigation of the genome wide associated schizophrenia risk variant NRG1 rs12807809. <i>Schizophrenia Research</i> , 2011 , 125, 304-6	3.6	20
186	Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. <i>Journal of Psychiatric Research</i> , 2011 , 45, 1639-47	5.2	20
185	Markers from event-related potential subcomponents and reaction time for information processing dysfunction in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998 , 248, 307-13	5.1	20
184	Long-acting risperidone: focus on safety. <i>Clinical Therapeutics</i> , 2006 , 28, 633-51	3.5	20
183	Effects of antidepressant pharmacotherapy after repetitive transcranial magnetic stimulation in major depression: an open follow-up study. <i>Journal of Psychiatric Research</i> , 2003 , 37, 145-53	5.2	20
182	Cincinnati criteria for mixed mania and suicidality in patients with acute mania. <i>Comprehensive Psychiatry</i> , 2004 , 45, 62-9	7.3	20
181	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 5-18	5.1	19
180	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 19-26	5.1	19
179	Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue. <i>Journal of Psychopharmacology</i> , 2012 , 26, 744-50	4.6	19
178	Problems associated with the classification and diagnosis of psychiatric disorders. <i>World Journal of Biological Psychiatry</i> , 2005 , 6, 45-56	3.8	19
177	Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism. <i>PLoS ONE</i> , 2013 , 8, e59395	3.7	18
176	Reception of Kraepelin's ideas 1900-1960. <i>Psychiatry and Clinical Neurosciences</i> , 2011 , 65, 318-25	6.2	18
175	Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT. <i>Psychiatry Research - Neuroimaging</i> , 2009 , 173, 183-9	2.9	18
174	Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 477-83	5.8	18
173	Duloxetine: a new selective and dual-acting antidepressant. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 421-7	4	18
172	Handedness and corpus callosum morphology. <i>Psychiatry Research - Neuroimaging</i> , 2002 , 116, 33-42	2.9	18
171	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 13-22	5.1	17
170	Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episode. <i>European Neuropsychopharmacology</i> , 2013 , 23, 663-74	1.2	17

169	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015 , 19, 158-67	2.4	17
168	Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. <i>Journal of Affective Disorders</i> , 2015 , 173, 126-33	6.6	17
167	Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2008 , 23, 95-105	2.2	17
166	Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 195-204	2.2	17
165	Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 814-821	5.8	17
164	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015 , 19, 2-7	2.4	16
163	Obsessive-compulsive disorder--A question of conscience? An fMRI study of behavioural and neurofunctional correlates of shame and guilt. <i>Journal of Psychiatric Research</i> , 2015 , 68, 354-62	5.2	16
162	Schizotypy and behavioural adjustment and the role of neuroticism. <i>PLoS ONE</i> , 2012 , 7, e30078	3.7	16
161	Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 180-95	3.8	16
160	Meta-analyses: a method to maximise the evidence from clinical studies?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 17-23	5.1	16
159	Tachykinin receptor 1 variants associated with aggression in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 757-61	3.5	16
158	The impact of the duration of untreated psychosis on short- and long-term outcome in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2003 , 16, S39-S43	4.9	16
157	Familial cosegregation of affective disorder and Hailey-Hailey disease. <i>British Journal of Psychiatry</i> , 1993 , 163, 109-10	5.4	16
156	Anxiolytic effects of vigabatrin in panic disorder. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 539-40.7	4.7	16
155	Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. <i>Microbial Biotechnology</i> , 2016 , 10, 17-27	3.3	15
154	Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 85-92	5.1	15
153	Neuropsychological functioning in inpatients with major depression or schizophrenia. <i>BMC Psychiatry</i> , 2013 , 13, 203	4.2	15
152	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 65-74	5.1	15

151	What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 107-16	5.1	15
150	Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial. <i>Psychiatric Quarterly</i> , 2012 , 83, 187-207	4.1	15
149	Prediction of symptom remission in schizophrenia during inpatient treatment. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 426-34	3.8	15
148	Cardiovascular disease and diabetes in people with severe mental illness. <i>Revista De Psiquiatria Y Salud Mental</i> , 2009 , 2, 49-59	2.7	15
147	Deficit states in schizophrenia and their association with the length of illness and gender. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 272-8	5.1	15
146	Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1425-33	4.6	15
145	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 2-16	3.8	15
144	Mobility behaviour and driving status of patients with mental disorders - an exploratory study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016 , 20, 40-6	2.4	14
143	Intact emotion-cognition interaction in schizophrenia patients and first-degree relatives: evidence from an emotional antisaccade task. <i>Brain and Cognition</i> , 2013 , 82, 329-36	2.7	14
142	Distinct seasonality of depressive episodes differentiates unipolar depressive patients with and without depressive mixed states. <i>Journal of Affective Disorders</i> , 2006 , 90, 1-5	6.6	14
141	A Randomized Controlled Trial of Group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: Results of a 2-Year Follow-up. <i>Schizophrenia Bulletin</i> , 2016 , 42 Suppl 1, S71-80	1.3	14
140	No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 405-12	5.1	13
139	Combining the categorical and the dimensional perspective in a diagnostic map of psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261, 3-10	5.1	13
138	The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 447-456	3.8	13
137	Creating a map of psychiatric patients based on psychopathological symptom profiles. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259, 164-71	5.1	13
136	Anterior cingulum volumetry, auditory P300 in schizophrenia with negative symptoms. <i>Psychiatry Research - Neuroimaging</i> , 2010 , 183, 133-9	2.9	13
135	Electroencephalography as a diagnostic instrument in Alzheimer's disease: reviews and perspectives. <i>International Psychogeriatrics</i> , 1997 , 9 Suppl 1, 237-46; discussion 247-52	3.4	13
134	Estrogen receptor gene 1 variants are not associated with suicidal behavior. <i>Psychiatry Research</i> , 2008 , 160, 1-7	9.9	13

133	White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 278-84	5.1	13
132	The forthcoming revision of the diagnostic and classificatory system: perspectives based on the European psychiatric tradition. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 5, 7-17	5.1	13
131	Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147, 308-15	3.5	13
130	Corpus callosum measurement as an in vivo indicator for neocortical neuronal integrity, but not white matter pathology, in Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 470-6	6.5	13
129	The German Research Network on Schizophrenia--impact on the management of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2006 , 8, 115-21	5.7	13
128	Exploring the structure of psychopathological symptoms: a re-analysis of AMDP data by robust nonmetric multidimensional scaling. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 227-38	5.1	12
127	Influence of anxiety on electrophysiological correlates of response inhibition capacities in alcoholism. <i>Clinical EEG and Neuroscience</i> , 2007 , 38, 89-95	2.3	12
126	Fifteen-year follow-up of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorders: the prognostic significance of psychotic features. <i>Comprehensive Psychiatry</i> , 2005 , 46, 322-7	7.3	12
125	Improving the chance of recovery from the short- and long-term consequences of depression. <i>International Clinical Psychopharmacology</i> , 2003 , 18, 219-25	2.2	12
124	A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 29-38	3.8	11
123	[123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 40-7	5.1	11
122	Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?. <i>Pharmacopsychiatry</i> , 2004 , 37, 110-8	2	11
121	Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis. <i>Methods</i> , 2012 , 56, 519-27	4.6	10
120	Attention to emotion: auditory-evoked potentials in an emotional choice reaction task and personality traits as assessed by the NEO FFI. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261, 111-20	5.1	10
119	NCAM1, TACR1 and NOS genes and temperament: a study on suicide attempters and controls. <i>Neuropsychobiology</i> , 2011 , 64, 32-7	4	10
118	Antipsychotic response in the first week predicts later efficacy. <i>Neuropsychobiology</i> , 2012 , 66, 100-5	4	10
117	SNAP-25 genotype influences NAA/Cho in left hippocampus. <i>Journal of Neural Transmission</i> , 2008 , 115, 1513-8	4.3	10
116	Drug Treatment of Depressive Symptoms in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008 , 1, 328-340	1.6	10

115	Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1 year after their first in-patient treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019 , 269, 459-468	5.1	10
114	Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. <i>Cognitive Neuropsychiatry</i> , 2017 , 22, 280-297	2	9
113	Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study. <i>NeuroImage: Clinical</i> , 2019 , 21, 101624	5.3	9
112	The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014 , 18, 78-85	2.4	9
111	Interference control in adult ADHD: no evidence for interference control deficits if response speed is controlled by delta plots. <i>Acta Psychologica</i> , 2013 , 143, 71-8	1.7	9
110	Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. <i>BMC Medicine</i> , 2012 , 10, 67	11.4	9
109	Is evaluation of humorous stimuli associated with frontal cortex morphology? A pilot study using facial micro-movement analysis and MRI. <i>Cortex</i> , 2011 , 47, 569-74	3.8	9
108	Is evidence sufficient for evidence-based medicine?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259 Suppl 2, S167-72	5.1	9
107	Platelet monoamine oxidase activity in alcoholics with and without a family history of alcoholism. <i>European Addiction Research</i> , 2000 , 6, 57-63	4.6	9
106	Biological Perspectives on Psychiatry for the Person. <i>International Journal of Person Centered Medicine</i> , 2011 , 1,		9
105	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 51, 190-5	5.5	8
104	Study design features affecting outcome in antidepressant trials. <i>Journal of Affective Disorders</i> , 2012 , 141, 160-7	6.6	8
103	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. <i>Psychiatry Research</i> , 2010 , 179, 222-5	9.9	8
102	Antidepressants and suicidality in younger adults--is bipolar illness the missing link?. <i>Acta Psychiatrica Scandinavica</i> , 2009 , 119, 166; author reply 167	6.5	8
101	Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression. <i>Acta Neuropsychiatrica</i> , 2003 , 15, 217-26	3.9	8
100	Translations of Measurements and Scales: Opportunities and Diversities. <i>International Psychogeriatrics</i> , 2000 , 12, 391-394	3.4	8
99	The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals?. <i>Psychiatria Danubina</i> , 2016 , 28, 435-440	1.8	8
98	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , 2016 , 249, 84-90	2.9	7

97	Driving ability according to German guidelines in stabilized bipolar I and II outpatients receiving lithium or lamotrigine. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 459-62	2.9	7
96	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009 , 150B, 434-8	3.5	7
95	Prefrontal cortex stimulation as antidepressant treatment: mode of action and clinical effectiveness of rTMS. <i>Supplements To Clinical Neurophysiology</i> , 2003 , 56, 406-32		7
94	Methodological issues in psychiatry: psychiatry as an empirical science. <i>World Journal of Biological Psychiatry</i> , 2001 , 2, 38-47	3.8	7
93	Brofaromine. <i>CNS Drugs</i> , 1995 , 3, 1-8	6.7	7
92	No association of a set of candidate genes on haloperidol side effects. <i>PLoS ONE</i> , 2012 , 7, e44853	3.7	7
91	A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients - Results from the German Algorithm Project (GAP3). <i>Journal of Affective Disorders</i> , 2018 , 228, 173-177	6.6	7
90	Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. <i>BMC Psychiatry</i> , 2016 , 16, 153	4.2	6
89	Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 303-313	5.1	6
88	Are antidepressants clinically useful? Conclusion of a decade of debate. <i>World Psychiatry</i> , 2014 , 13, 201-244	4.4	6
87	Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011 , 35, 74-7	5.5	6
86	Tyrosine hydroxylase and DOPA decarboxylase gene variants in personality traits. <i>Neuropsychobiology</i> , 2009 , 59, 23-7	4	6
85	Brofaromine versus imipramine in in-patients with major depression--a controlled trial. <i>Journal of Affective Disorders</i> , 1997 , 44, 91-9	6.6	6
84	Psychomotor Performance Under Neuroleptic Treatment in Schizophrenia. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2001 , 12, 49-53	0.5	6
83	Critical trial-related criteria in acute schizophrenia studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 151-5	5.1	5
82	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm". <i>International Journal of Psychiatry in Clinical Practice</i> , 2013 , 17, 78-89	2.4	5
81	Psychoedukation bei Personen mit erhöhtem Psychoseerisiko. <i>Psychotherapeut</i> , 2012 , 57, 326-334	0.5	5
80	How close is evidence to truth in evidence-based treatment of mental disorders?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 277-89	5.1	5

79	Antidepressants vs. placebo: not merely a quantitative difference in response. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 1435-1437	5.8	5
78	Driving ability in schizophrenic patients: effects of neuroleptics. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005 , 9, 168-74	2.4	5
77	The ongoing discussion on termination of life on request. A review from a German/European perspective. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021 , 25, 2-18	2.4	5
76	Efficacy of extended clinical management, group CBT, and group plus individual CBT for major depression: Results of a two-year follow-up study. <i>Journal of Affective Disorders</i> , 2018 , 238, 570-578	6.6	4
75	Infectious Agents are Associated with Psychiatric Diseases. <i>Mental Illness</i> , 2012 , 4, e10	0.9	4
74	The value of selective serotonin re-uptake inhibitors (SSRIs) in the treatment of panic disorder with and without agoraphobia. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997 , 1, 59-67	2.4	4
73	Saccadic eye velocity after selective GABAergic treatment with tiagabine in healthy volunteers. <i>Neuropsychobiology</i> , 2005 , 52, 147-50	4	4
72	Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis. <i>Microbial Biotechnology</i> , 2019 , 13, 120-127	3.3	4
71	Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?. <i>Pharmacopsychiatry</i> , 2017 , 50, 136-144	2	3
70	The potential role of Marginal Structural Models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 386-95	3.8	3
69	Pharmacotherapy of schizophrenic patients: achievements, unsolved needs, future research necessities. <i>Current Pharmaceutical Biotechnology</i> , 2012 , 13, 1476-89	2.6	3
68	A review of the reversible MAO-A inhibitor moclobemide in geriatric patients. <i>Human Psychopharmacology</i> , 1998 , 13, 43-51	2.3	3
67	Psychopharmacological therapy and suicide of inpatients with depressive psychoses. <i>Archives of Suicide Research</i> , 1998 , 4, 143-155	2.3	3
66	The assessment of cognitive impairment would be a relevant addition to the criteria for diagnosing schizophrenia. <i>World Psychiatry</i> , 2008 , 7, 35-6	14.4	3
65	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo. <i>Revista De Psiquiatria Clínica</i> , 2006 , 33, 7-64	0.8	3
64	The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 334-40	5.1	3
63	Effects of different antidepressant treatments on the core of depression. <i>Dialogues in Clinical Neuroscience</i> , 2008 , 10, 309-20	5.7	3
62	Is the Overlap of Neurobiological and Psychopathological Parameters Large Enough to Give up the Dichotomic Classification?. <i>Psychiatric Annals</i> , 2010 , 40, 163-167	0.5	3

61	What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020 , 270, 661-671	5.1	3
60	Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods. <i>International Journal of Methods in Psychiatric Research</i> , 2016 , 25, 3-11	4.3	3
59	Psychoeducational and Cognitive Behavioral Treatment Programs: Implementation and Evaluation From 1995 to 2015 in Kraepelin's Former Hospital. <i>Schizophrenia Bulletin</i> , 2016 , 42 Suppl 1, S81-9	1.3	3
58	No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 171-180	5.8	3
57	Why are new antidepressants failing to make the grade for approval?. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 641-643	4	2
56	Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. <i>Schizophrenia Research</i> , 2019 , 209, 185-192	3.6	2
55	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. <i>Psychopharmacology</i> , 2011 , 214, 719-28	4.7	2
54	Review: antidepressants associated with increased risk of suicidality in adults aged less than 25 years. <i>Evidence-Based Mental Health</i> , 2010 , 13, 52	11.1	2
53	Safety evaluation of zotepine for the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 659-66	4.1	2
52	Cardiovascular disease and diabetes in people with severe mental illness. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2009 , 2, 49-59	0.2	2
51	Possibilities and limitations of DSM-5 in improving the classification and diagnosis of mental disorders. <i>Psychiatria Polska</i> , 2018 , 52, 611-628	1.3	2
50	Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. <i>Journal of Psychiatric Research</i> , 2021 , 136, 543-551	5.2	2
49	Medication management of antipsychotic treatment in schizophrenia: A narrative review. <i>Human Psychopharmacology</i> , 2021 , 36, e2765	2.3	2
48	Treatment-resistant Depression 2013 , 21-41		1
47	Effectiveness of quetiapine in outpatients with schizophrenia assessed under "real-life" conditions: a German clinical-practice evaluation programme. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 120-127	1.7	1
46	The problem of being a paradigm: the emergence of neural stem cells as example for Kuhnian revolution in biology or misconception of the scientific community?. <i>Poiesis & Praxis</i> , 2009 , 6, 3-11		1
45	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. <i>Focus (American Psychiatric Publishing)</i> , 2011 , 9, 500-525	1.1	1
44	Optimierung der pharmakologischen Langzeitbehandlung ersterkrankter schizophrener Patienten. <i>Psychoneuro: Psychiatrie - Neurologie - Psychotherapie</i> , 2004 , 30, 615-619		1

43	Dementia Treatment: A German Perspective on Psychosocial Aspects and Therapeutic Approaches. <i>International Psychogeriatrics</i> , 1995 , 7, 459-470	3.4	1
42	Involvement of mesial-temporal structures in rapid cycling mood disorders?. <i>Human Psychopharmacology</i> , 1995 , 10, 475-480	2.3	1
41	Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. <i>Journal of Affective Disorders</i> , 2021 , 299, 73-84	6.6	1
40	Das Publizieren in der Psychiatrie 2006 , 199-221		1
39	Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs) 1993 , 163-182		1
38	Side effect burden of antipsychotic medication. <i>Medical Psychiatry</i> , 2009 , 231-259		1
37	Polymorphisms in CRYBB2 encoding B2-crystallin are associated with antisaccade performance and memory function. <i>Translational Psychiatry</i> , 2020 , 10, 113	8.6	1
36	Subsyndromal generalised anxiety disorder: operationalisation and epidemiology - a systematic literature survey. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021 , 1-10	2.4	1
35	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022 , 1	5.1	1
34	Classification Systems of Mental Disorders: Where Did We Go Wrong? 2020 , 193-203		0
33	¿Predice la mejoría precoz inducida por los antidepressivos la respuesta/remisión? Análisis de los datos de un estudio naturalista en una muestra a gran escala de pacientes hospitalizados con depresión mayor,. <i>Psiquiatria Biologica</i> , 2010 , 17, 45-53	0.2	
32	Do "real world" studies on antipsychotics tell us the real truth?. <i>World Psychiatry</i> , 2009 , 8, 32	14.4	
31	Propentofylline. <i>CNS Drugs</i> , 1997 , 8, 265	6.7	
30	Psychopharmacological therapy and suicide of inpatients with depressive psychoses. <i>Archives of Suicide Research</i> , 1998 , 4, 143-155	2.3	
29	Neurobiologische Befunde und klinische Ergebnisse. <i>Psycho</i> , 2003 , 29, 44-50		
28	Response to letter to the editor from Andrade et al. (2003) ECT in the management of major depression: Implications of recent research, <i>World J Biol Psychiatry</i> 4: 139-140. <i>World Journal of Biological Psychiatry</i> , 2003 , 4, 140-141	3.8	
27	Past, present and future of biological psychiatry. <i>World Journal of Biological Psychiatry</i> , 2001 , 2, 156-8	3.8	
26	Antidepressant treatment of bipolar depression 2000 , 387-403		

- 25 Schizophrene und schizophreniforme Störungen **2005**, 1342-1351
- 24 Schizophrene und schizophreniforme Störungen **2007**, 1507-1518
- 23 Angststörungen **2008**, 911-925
- 22 Psychiatrische Erkrankungen **2003**, 1265-1384
- 21 Schizoaffektive Psychosen und sonstige wahnhaft Störungen nicht organischer Genese **2004**, 160-188
- 20 Schizophrene Psychosen **2004**, 109-160
- 19 Extrapiramidal-motorische Störungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie **2004**, 19-60
- 18 Evaluación clínica de los síntomas negativos de la esquizofrenia. *European Psychiatry (Ed Española)*, **2007**, 14, 375-382
- 17 Prinzipien der Methodik empirischer Forschung in der Psychiatrie **2015**, 1-28
- 16 Standardisierte Befunddiagnostik in der Psychiatrie **2015**, 1-25
- 15 Psychiatric Assessment: Negative Symptoms **2015**, 290-294
- 14 Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie **2016**, 1-18
- 13 Psychiatrie, Psychosomatik, Psychotherapie [Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes **2016**, 1-35
- 12 Psychiatrie, Psychosomatik, Psychotherapie [Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes **2017**, 3-37
- 11 Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie **2017**, 1321-1338
- 10 Psychopharmakotherapie [klinisch-empirische Grundlagen **2017**, 795-842
- 9 Prinzipien der Methodik empirischer Forschung in der Psychiatrie **2017**, 463-490
- 8 Standardisierte Befunddiagnostik in der Psychiatrie **2017**, 577-600

- 7 Der besondere Stellenwert von Antipsychotika der zweiten Generation in der Therapie schizophrener und affektiver Psychosen **2010**, 187-196
- 6 Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients **2011**, 93-107
- 5 Suicidality and Outcome in Schizophrenia Patients **2011**, 365-382
- 4 Psychiatrie in Europa: Stand der Dinge, Chancen und Herausforderungen **2012**, 219-227
- 3 Antipsychotic Treatment Within a Naturalistic Trial How Are We Treating Schizophrenia Patients in the Real-World? **2013**, 137-156
- 2 Correspondence (reply): In reply. *Deutsches Arzteblatt International*, **2013**, 110, 610-1 2.5
- 1 Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. *Pharmacopsychiatry*, **2019**, 52, 180-185 2